CN101912616B - Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof - Google Patents
Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof Download PDFInfo
- Publication number
- CN101912616B CN101912616B CN2010102577462A CN201010257746A CN101912616B CN 101912616 B CN101912616 B CN 101912616B CN 2010102577462 A CN2010102577462 A CN 2010102577462A CN 201010257746 A CN201010257746 A CN 201010257746A CN 101912616 B CN101912616 B CN 101912616B
- Authority
- CN
- China
- Prior art keywords
- alpha
- tocopherol
- mesoporous silicon
- still
- supercritical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an alpha-tocopheryl mesoporous silicon compound using a supercritical CO2 injection method and a preparation method thereof, belonging to the technical field of medicines. The preparation method comprises a step of preparing alpha-tocopheryl and mesoporous silicon into the alpha-tocopheryl mesoporous silicon compound under the environment of carbon dioxide by means of the supercritical carbon dioxide injection method. The drug-loading rate of the compound prepared by using the method of the invention is 0.58-0.76g/g. The alpha-tocopheryl/mesoporous silicon compound prepared by using the supercritical CO2 injection method can be prepared into food additives with various functions. The process has the advantages of simple process for preparing the compound, high drug-loading rate and no solvent residues, and the compound is a solid formulation.
Description
Technical field
What the present invention relates to is complex of a kind of medical technical field and preparation method thereof, specifically is a kind of supercritical CO
2Injection method alpha-tocopherol mesoporous silicon compound and preparation method thereof.
Background technology
Tocopherol has another name called vitamin E, is a kind of fatsoluble vitamin.Natural Vitamin E has 8 kinds of analog, and is wherein commonly used and biological activity is the highest with alpha-tocopherol.Except that having significant non-oxidizability, alpha-tocopherol can also be eliminated intravital free radical, angiocardiopathy preventing and cancer.Because the free phenolic hydroxyl group of alpha-tocopherol is prone at oxidant, generate quinoid under the action of ultraviolet ray and lost efficacy, therefore be necessary that the polymer of tocopherol and biocompatibility is processed complex improves its stability; In addition, tocopherol is in a liquid state at normal temperatures, and extremely difficulty is disperseed in water, processes solid composite and can also improve its dispersibility in water.
Mesoporous silica nano-particle has specific pore passage structure, big specific surface area, thereby have good permeability, and adsorptivity is commonly used to do the carrier of drug sustained release system.The common method of preparation mesoporous silicon compound is a liquid immersion method.But in the process of preparation complex, adopt liquid immersion method may destroy tocopherol, and possible organic solvent residual, limited the application of product.To the problems referred to above, supercritical fluid technology is suggested and is used to prepare nano-complex, and supercritical fluid technology has been widely used in the preparation research of active substance as a kind of technology of cleaning.Critical temperature that supercritical carbon dioxide is moderate and noble gas character can be avoided thermal sensitivity and the destruction that is prone to oxidized material; Its low viscosity, low surface tension and high osmosis and need not subsequent treatment have been saved the time greatly and have been improved efficient.At present, do not find to use supercritical CO as yet
2Injection method prepares the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.
Summary of the invention
The present invention is directed to the above-mentioned deficiency that prior art exists, a kind of supercritical CO is provided
2Injection method alpha-tocopherol mesoporous silicon compound and preparation method thereof, its drug loading are 0.58～0.76g/g.Adopt supercritical CO
2Injection method prepares alpha-tocopherol/mesoporous silicon-immobilized nanocrystal composition, can be prepared into various function food additives.This prepared complex flow process is simple, and drug loading is high, and no solvent residue is solid dosage forms.
The present invention realizes that through following technical scheme the present invention processes the alpha-tocopherol mesoporous silicon compound through the supercritical carbon dioxide injection method with alpha-tocopherol and mesoporous silicon under carbon dioxide environment.
Described supercritical carbon dioxide injection method is meant: alpha-tocopherol and mesoporous silicon are placed feeding CO in back on the sintered plate that injects still
2Gas is to discharge the air that injects in the still, then with CO
2Pump into and inject still, after reaching supercritical temperature pressure, the ON cycle pump 1h that circulates, slowly the about 1h of pressure release promptly obtains the alpha-tocopherol mesoporous silicon compound to normal pressure then.
Described alpha-tocopherol and mesoporous silicon ratio, its mass ratio is 14: 1;
Described supercritical temperature pressure is meant: the carbon dioxide environment of 12～20Mpa and 30～55 ℃.
The component and the content of the alpha-tocopherol mesoporous silicon compound that the inventive method prepares are: it is that 0.58～0.76g and complex are pressed powder that every g complex contains alpha-tocopherol.
The present invention is simple to operate, and the alpha-tocopherol mesoporous silicon compound that makes is a solid composite, and no solvent residue can be applicable to various dosage forms or adds various food.
The specific embodiment
Elaborate in the face of embodiments of the invention down, present embodiment provided detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following embodiment being to implement under the prerequisite with technical scheme of the present invention.
Detection method of the present invention is a ultraviolet spectrophotometer.Ultraviolet spectrophotometer is Shanghai Spectrum Apparatus Co., Ltd.; The detection wavelength is 292cm; Solvent is a dehydrated alcohol, and standard curve is A=0.00653*C-0.01116, and the drug loading of alpha-tocopherol is the alpha-tocopherol quality/alpha-tocopherol mesoporous silicon compound quality of load.
Embodiment 1
Taking by weighing mass ratio is about 1: 14 mesoporous silicon (603m2/g, 0.84cm3/g 5.95nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 30 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.
Drug loading is measured: take by weighing the mesoporous silicon-immobilized nanocrystal composition of a certain amount of alpha-tocopherol, be dissolved in the dehydrated alcohol, survey solution absorbency at the 292cm place with ultraviolet spectrophotometer.According to the standard curve A=0.00653*C-0.01116 of alpha-tocopherol under this wavelength, calculating drug loading is 67.76%.The result lists in the table 1.
Embodiment 2
Taking by weighing mass ratio is about 1: 14 mesoporous silicon (603m2/g, 0.84cm3/g 5.95nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 12MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 63.86%, and the result lists in the table 1.
Embodiment 3
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (603m
2/ g, 0.84cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 15MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 69.53%, and the result lists in the table 1.
Embodiment 4
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (603m
2/ g, 0.84cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 76.14%, and the result lists in the table 1.
Embodiment 5
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (86m
2/ g, 0.54cm
3/ g 25nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 58.30%, and the result lists in the table 1.
Embodiment 6
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (576m
2/ g, 0.85cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly pressure release is collected the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 73.05%, and the result lists in the table 1.
Embodiment 7
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (449m
2/ g, 1.95cm
3/ g 17nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 79.88%, and the result lists in the table 1.
Embodiment 8
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (603m
2/ g, 0.84cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 35 ℃, valve-off when pressure is 20MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly pressure release is collected the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 74.93%, and the result lists in the table 1.
Embodiment 9
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (603m
2/ g, 0.84cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 45 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 63.77%, and the result lists in the table 1.
Embodiment 10
Take by weighing mass ratio and be about 1: 14 mesoporous silicon (603m
2/ g, 0.84cm
3/ g 6nm) and alpha-tocopherol, is put on the sintered plate that injects the still different layers.In reaction system, lead to CO
2About 2min is to discharge the air in the still.With CO
2Pump into and inject still, wait to inject that the still temperature reaches 55 ℃, valve-off when pressure is 18MPa, the ON cycle pump; Circulate after 1 hour, close circulating pump, open valve; Slowly the about 1h of pressure release collects the granule that injects in the still to normal pressure, promptly obtains the mesoporous silicon-immobilized nanocrystal composition of alpha-tocopherol.Drug loading is measured with embodiment 1, and the drug loading that calculates is 60.55%, and the result lists in the table 1.
Table 1
| Embodiment | Temperature | Pressure | Drug loading % |
| 1 | 30 | 18 | 67.76 |
| 2 | 35 | 12 | 63.86 |
| 3 | 35 | 15 | 69.53 |
| 4 | 35 | 18 | 76.14 |
| 5 | 35 | 18 | 58.30 |
| 6 | 35 | 18 | 73.05 |
| 7 | 35 | 18 | 79.88 |
| 8 | 35 | 20 | 74.93 |
| 9 | 45 | 18 | 63.77 |
| 10 | 55 | 18 | 60.55 |
Claims (2)
1. supercritical CO
2The method for preparing of injection method alpha-tocopherol mesoporous silicon compound is characterized in that, through the supercritical carbon dioxide injection method alpha-tocopherol and mesoporous silicon is processed the alpha-tocopherol mesoporous silicon compound under carbon dioxide environment;
Described supercritical carbon dioxide injection method is meant: alpha-tocopherol and mesoporous silicon are placed feeding CO in back on the sintered plate that injects still
2Gas is to discharge the air that injects in the still, then with CO
2Pump into and inject still, after reaching supercritical temperature pressure, the ON cycle pump 1h that circulates, slowly the about 1h of pressure release promptly obtains the alpha-tocopherol mesoporous silicon compound to normal pressure then;
Described alpha-tocopherol and mesoporous silicon ratio, its mass ratio is 14: 1;
Described supercritical temperature pressure is meant: the carbon dioxide environment of 12～20Mpa and 30～55 ℃.
2. supercritical CO
2Injection method alpha-tocopherol mesoporous silicon compound is characterized in that, prepares through the said method of claim 1, and the mass percentage content of alpha-tocopherol wherein is 58%～76%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102577462A CN101912616B (en) | 2010-08-20 | 2010-08-20 | Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102577462A CN101912616B (en) | 2010-08-20 | 2010-08-20 | Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101912616A CN101912616A (en) | 2010-12-15 |
| CN101912616B true CN101912616B (en) | 2012-01-04 |
Family
ID=43320360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102577462A Expired - Fee Related CN101912616B (en) | 2010-08-20 | 2010-08-20 | Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101912616B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103060094A (en) * | 2013-01-14 | 2013-04-24 | 福建正盛无机材料股份有限公司 | Preparation method of menthol/SiO2 as tobacco flavor sustained-release material |
| CN111714540A (en) * | 2020-05-27 | 2020-09-29 | 中山大学 | Volatile oil substance micro-nano drug delivery system and preparation method and application thereof |
| CN111803696B (en) * | 2020-07-10 | 2022-02-18 | 中山大学 | Preparation method of patchouli oil nano composite membrane for skin wound repair |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7172770B2 (en) * | 2001-02-19 | 2007-02-06 | Board Of Regents, The University Of Texas System | Mesoporous compositions for use in drug delivery |
| CN1140259C (en) * | 2001-06-05 | 2004-03-03 | 北京中阳德安医药科技有限公司 | Nm cosmetic |
| CN101721707B (en) * | 2009-11-30 | 2012-09-05 | 上海交通大学 | Preparation method of pH response drug release carrier on basis of coordinate bond |
| CN101732326B (en) * | 2009-12-17 | 2011-04-20 | 上海交通大学 | Method for preparing vitamin D3 nutrient complex |
-
2010
- 2010-08-20 CN CN2010102577462A patent/CN101912616B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101912616A (en) | 2010-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sahne et al. | Extraction of bioactive compound curcumin from turmeric (Curcuma longa L.) via different routes: A comparative study | |
| Xia et al. | Determination of phenolic acids in Prunella vulgaris L.: a safe and green extraction method using alcohol-based deep eutectic solvents | |
| CN101912616B (en) | Alpha-tocopheryl mesoporous silicon compound using supercritical CO2 injection method and preparation method thereof | |
| CN107628959B (en) | Choline eutectic solvent, preparation method and application in extraction of globeflower flavone C-glycoside | |
| Malapermal et al. | Biosynthesis of bimetallic Au-Ag nanoparticles using Ocimum basilicum (L.) with antidiabetic and antimicrobial properties | |
| JP2010006783A (en) | Method and apparatus for extracting fucoxanthin from seaweed | |
| TW200621310A (en) | A process for preparing formulations of lypophilic active substances by spray freeze drying | |
| CN104628698A (en) | Preparation method and application of proanthocyanidin extract in grapes | |
| CN103989635A (en) | Method for preparing coenzyme Q10 lipidosome through supercritical carbon dioxide | |
| Zeng et al. | Electrospun polylactic acid/poly (ε-caprolactone) fibrous encapsulated thymol/MIL-68 (Al) as a food packaging material | |
| CN106137974B (en) | High activity inonotus obliquus powder and preparation method thereof | |
| CN108059148A (en) | The preparation method of nano-particle with Scavenging ability | |
| CN1795014A (en) | Method for the preparation of molecular complexes | |
| Jamaleddine et al. | In vitro bioactivities of extracts from tomato pomace | |
| CN102643259B (en) | Ultrasonic preparation method of myrica rubra leaf proanthocyanidin oligomer | |
| CN101053557A (en) | Noradrenaline bitartrate medicine composition frozen dried powder injection | |
| CN103494811B (en) | Sodium glycididazole composition and preparation method thereof | |
| CN101703464A (en) | Preparation method of high-concentration long-acting doxycycline injection adopting low organic solvent | |
| CN108117772A (en) | A kind of garlic pigment extract to DNA damage with protective effect | |
| CN107952466A (en) | In methods of the h-BN as catalyst reduction p-nitrophenol for loading Au or Pd | |
| CN105395477A (en) | Docetaxel injection and preparation method thereof | |
| CN107929246B (en) | Antioxidant coenzyme Q10 freeze-dried powder and production process thereof | |
| KR20220029834A (en) | A method manufacturing composite nanoparticle comprising vitamin C and fucoidan | |
| CN103239392B (en) | Ornidazole injection preparation and preparation method thereof | |
| Herbina et al. | Intensification of the Extraction Process of Flavonoids and Hydroxycinnamic Acids from Tanacetum vulgare L. Flowers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG RUIZHI SUPERCRITICAL TECHNOLOGY DEVELOPMEN Free format text: FORMER OWNER: SHANGHAI JIAO TONG UNIVERSITY Effective date: 20150410 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200240 MINHANG, SHANGHAI TO: 226600 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150410 Address after: 9 groups of Guanghua village of Haian town Haian County Jiangsu city Nantong province 226600 Patentee after: Nantong Ruizhi Supercritical Technology Development Co., Ltd. Address before: 200240 Dongchuan Road, Shanghai, No. 800, No. Patentee before: Shanghai Jiao Tong University |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20190820 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |